How much cash does Cullinan Therapeutics, Inc. generate?

Cullinan Therapeutics, Inc. (CGEM) generated -$178.6M in operating cash flow over the trailing twelve months.

What is Cullinan Therapeutics, Inc.'s free cash flow?

After $11.0K of capital expenditures, Cullinan Therapeutics, Inc.'s free cash flow was -$145.2M over the trailing twelve months, down 19.4% year over year.

Where does Cullinan Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Cullinan Therapeutics, Inc. CGEM Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$221.04M-0.5%	-$219.88M-1.4%	-$216.81M-4.9%	-$206.76M-15.7%	-$178.74M-6.7%
Depreciation and amortization	$314K+1.0%	$311K+0.6%	$309K+1.0%	$306K0.0%	$306K0.0%
Stock-based compensation	$34.28M-4.9%	$36.04M-6.1%	$38.36M+0.1%	$38.33M-1.7%	$38.97M+3.0%
Change in accounts payable	——	——	——	——	——
Change in other assets	-$4.49M+34.9%	-$6.9M-56.0%	-$4.42M—	——	——
Net cash from operating activities	-$178.64M-1.6%	-$175.75M-0.9%	-$174.27M-1.6%	-$171.53M-14.2%	-$150.21M-3.4%
Capital expenditures	——	——	——	——	——
Purchases of investments	$130.83M-44.7%	$236.53M-38.6%	$384.97M-18.0%	$469.2M-34.4%	$715.6M-0.8%
Net cash from investing activities	$175.6M-2.4%	$179.99M—	——	——	——
Proceeds from issuance of common stock	——	——	——	——	——
Distributions to noncontrolling interests	——	——	——	——	——
Net cash from financing activities	$1.47M+34.9%	$1.09M-44.3%	$1.96M-40.4%	$3.28M-98.8%	$265.1M-0.4%
Net increase (decrease) in cash	——	——	$1.25M+103%	-$42.2M-1,839%	$2.43M+116%
Income taxes paid	——	——	——	——	——
Increase Decrease In Accrued Expenses And Other Current Liabilities	$8.97M+11.8%	$8.03M-8.1%	$8.73M+174%	$3.19M-38.4%	$5.17M+78.5%
Increase (Decrease) in Prepaid Expense and Other Assets	-$4.49M+34.9%	-$6.9M-56.0%	-$4.42M—	——	——
Proceeds From Net Issuance Of Common Stock Under Equity Based Compensation Plans	$1.47M+34.9%	$1.09M-44.3%	$1.96M-50.3%	$3.94M-42.9%	$6.9M-13.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Cullinan Therapeutics, Inc. generate?: Cullinan Therapeutics, Inc. (CGEM) generated -$178.6M in operating cash flow over the trailing twelve months.
What is Cullinan Therapeutics, Inc.'s free cash flow?: After $11.0K of capital expenditures, Cullinan Therapeutics, Inc.'s free cash flow was -$145.2M over the trailing twelve months, down 19.4% year over year.
Where does Cullinan Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.